AbbVie (NYSE:ABBV) Issues FY 2026 Earnings Guidance

09 Apr 2026, 19:28 by Jessica Moore · The Cerbat Gem

AbbVie (NYSE:ABBV – Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 13.960-14.160 for the period, compared to the consensus EPS estimate of 14.560. The company issued revenue guidance of -. AbbVie also updated its Q1 2026 guidance to 2.560-2.600 EPS.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ABBV. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a report on Tuesday, January 20th. Cantor Fitzgerald decreased their price objective on shares of AbbVie from $250.00 to $240.00 and set an “overweight” rating for the company in a report on Wednesday. Royal Bank Of Canada began coverage on shares of AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective for the company. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Finally, Morgan Stanley boosted their price objective on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $252.65.

Get Our Latest Report on ABBV

AbbVie Price Performance

Shares of AbbVie stock traded up $0.95 on Thursday, hitting $212.54. The company had a trading volume of 4,468,324 shares, compared to its average volume of 7,235,077. The firm has a market capitalization of $375.81 billion, a P/E ratio of 90.06, a P/E/G ratio of 0.73 and a beta of 0.38. AbbVie has a twelve month low of $164.96 and a twelve month high of $244.81. The stock has a 50-day moving average of $220.65 and a 200-day moving average of $224.11.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts predict that AbbVie will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is 293.22%.

Insider Activity at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.25% of the stock is owned by corporate insiders.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Analyst/coverage support — some outlets and analysts continue to call ABBV a buy or maintain overweight ratings despite recent volatility, citing durable cash flow and pipeline potential. This helps limit downside by keeping institutional demand steady. AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It’s A Buy, But With Caveats (Upgrade)
Positive Sentiment: Dividend profile remains a supporting story for long‑term holders — ABBV is highlighted as a reliable dividend payer (Aristocrat status and recent raises), which can attract income investors and underpin the share price. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
Positive Sentiment: Therapeutic momentum — new dermatology data for Skyrizi and Rinvoq, and favorable labeling updates, reinforce the company’s immunology growth story and potential upside longer term. Can AbbVie’s New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
Neutral Sentiment: Legal action to narrow drug‑discount eligibility — AbbVie filed suit seeking clearer rules on a U.S. drug discount program; this could protect pricing long term but creates near‑term legal uncertainty. Investors will watch the timing and likely impact on net pricing. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
Neutral Sentiment: Corporate/PR items (BOTOX community program, media coverage) and trending coverage (Zacks, Yahoo) keep the name in retail and institutional screens but are unlikely to move fundamentals immediately. BOTOX® Cosmetic Empowers Women Entrepreneurs
Negative Sentiment: Guidance cut — ABBV lowered Q1 2026 EPS guidance to $2.56–$2.60 (consensus ~ $3.01) and FY 2026 to $13.96–$14.16 (consensus ~ $14.56). That downward revision is the main near‑term catalyst for share weakness, reducing near‑term earnings visibility and prompting re‑rating risk. AbbVie: Lowered Guidance Is Just Noise – Reiterate Buy
Negative Sentiment: Pricing concessions and program participation — AbbVie has placed Humira on the TrumpRx program at steep discounts and is publicly navigating tariff/discount pressures. Those moves can protect access but may pressure margins and legacy product revenue in the near term. AbbVie Puts Humira on TrumpRx at Steep Discount

Institutional Investors Weigh In On AbbVie

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ABBV. Wellington Management Group LLP lifted its position in AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after buying an additional 8,646,424 shares in the last quarter. Raymond James Financial Inc. grew its holdings in shares of AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after acquiring an additional 2,753,312 shares in the last quarter. Amundi grew its holdings in shares of AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after acquiring an additional 1,414,621 shares in the last quarter. State Street Corp grew its holdings in shares of AbbVie by 1.4% in the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after acquiring an additional 1,119,274 shares in the last quarter. Finally, First Trust Advisors LP grew its holdings in shares of AbbVie by 170.2% in the 4th quarter. First Trust Advisors LP now owns 1,336,498 shares of the company’s stock valued at $305,377,000 after acquiring an additional 841,947 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

About AbbVie

(Get Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.